AFFIX Labs has closed a deal with seating systems manufacturer for commercial vehicles and public transport Franz Kiel for the use of anti-microbial coating Si-Quat to ensure protection against contagious microbes.
Franz Kiel GmbH, manufacturer of seats for buses and trains, will apply Si-Quat, a durable semi-permanent anti-microbial coating developed by AFFIX Labs to protect public transport interiors from contagious microbes such as the SARS-COV-2 virus, which can survive for up to 3 days on some surfaces, making regularly touched areas in public spaces potential hotspots for cross contamination.
Si-Quat is proven to kill 99.9% of bacteria and viruses, including SARS-COV-2, thus helping ensure that public transport is safer as people around the world begin getting back onto buses and trains and preventing cross contamination. The coating creates a durable layer of polymerized active ingredient that binds to walls, handles, furniture, and other key touch points, staying in place for up to 12 months.
The coating has been tested and certified to be effective against bacteria, viruses, and fungi, and has passed the rigorous EN45545-2 HL3 flammability norm for trains and REG118.3 for busses.
“We are delighted to be working with AFFIX Labs to roll out Si-Quat in public transport systems around the world. It’s easy to apply, it works and we have had great support from the AFFIX Labs team. We hope that our partnership can help to re-open countries and boost passengers trust in once again using public transport,” said Daniel Fräde, Kiel’s Sales Director Bus Division.
“By treating the vast fleets of vehicles that power the mass movement of people in countries all over the world, AFFIX and Kiel Seating can create safe transportation interiors which are a key component of national infrastructures. We are proud to be part of the global effort to build a more future-proof response to COVID-19, and other contagions that have the potential to cause pandemics” concluded Tom Sam, CEO of AFFIX Labs.